EVIDENCE LIBRARY
Midazolam in a Conditional Mouse Model: Separating Liver and Intestinal Metabolism
A genetically engineered mouse model used midazolam to investigate the separate contributions of liver and intestinal oxidative metabolism.
A genetically engineered mouse model used midazolam to investigate the separate contributions of liver and intestinal oxidative metabolism.
A controlled deletion strategy
Investigators manipulated cytochrome P450 reductase expression using different induction conditions. They then compared probe-drug pharmacokinetics when liver metabolism was affected alone or together with intestinal metabolism. Midazolam and nelfinavir results supported an intestinal contribution to oral bioavailability.
A mechanistic model has boundaries
The experiment helps isolate processes that are difficult to separate in ordinary clinical observations. It does not reproduce the full range of human disease, drug interactions, or chronic exposure. Genetic manipulation and the inducing agent are also part of the experimental system. For interpreting oral midazolam concentrations, the study supports considering first-pass metabolism beyond the liver. It cannot determine how much intestinal metabolism contributed in one patient or justify transferring a mouse exposure ratio directly into a human dose estimate.
Source paper
Original analysis of the supplied journal article, identified as PMC6949133.